In 2004, Gunn added a regular segment on biotechnology, BioTech Nation. It has emerged as the only regular weekly mainstream programming on biotech on the national and international scene, and features interviews with biotech leaders. In its regular feature: “BioIssue of the Week”, Gunn discusses the breaking news of the day with award-winning science journalist, David Ewing Duncan.
In the U.S., Tech Nation can be heard four times each weekend on the National Public Radio website’s 24-hour Program Stream (npr.org). It airs on nearly 200 public radio stations, with multiple airtimes on the NPR Channels on XM-Sirius Satellite Radio. Globally, Tech Nation is aired three times weekly on the NPR Channels of Sirius Internet Radio and airs 25 weekly to 177 countries via Armed Forces Radio International. Tech Nation podcasts remain permanently archived on the Internet, enabling anyone, anywhere to listen to these materials on demand.
-
This week on Biotech Nation, Dr. Lincoln Nadauld shares how Culmination Bio is using 9 million preserved tissue samples and decades of patient data to improve how we understand and treat diseases. From discovering patterns in cancer treatments to exploring breakthroughs in heart and autoimmune diseases, this unique approach is changing medicine.
-
What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia.
-
What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.
-
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.
-
40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.
-
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
-
This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.
-
Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born.
-
Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.
-
This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry.